Aduro Biotech, Inc. , a biopharmaceutical company with three distinct immunotherapy technologies, announced today a clinical collaboration with Merck . The companies will investigate the combination of CRS-207, Aduro's LADD based immunotherapy, with Merck's anti-PD-1 therapy KEYTRUDAA for the treatment of gastric cancer.
